VERU · Veru Inc.
$2.26
-0.05 (-2.16%)
At close · Jul 24
Market Cap
$37.08M
Shares
16.05M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$16.89M
+3.6%
FY2024
Net Income
-$22.73M
+39.9%
FY2025
Gross Margin
34.67%
-11.8pp
FY2024
Operating Margin
-214.19%
+361.3pp
FY2024
Diluted EPS
-$11.00
-4.8%
FY2023
Operating Cash Flow
-$30.04M
-38.6%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | $16.89M | $16.3M | $39.35M | $61.26M | $42.59M | $31.8M | $15.86M | $13.66M | $22.13M | $32.6M | $24.49M | $31.46M | $35.03M | $18.57K | $22.22M | $27.54M | |
| — | — | $11.03M | $8.73M | $8.76M | $13.33M | $11.81M | $10.15M | $7.09M | $6.64M | $8.78M | $13.63M | $11.37M | $13.95M | $14.41M | $8.7M | $9.3M | $14.03M | |
| — | — | $5.85M | $7.57M | $30.59M | $47.93M | $30.79M | $21.66M | $8.77M | $7.02M | $13.35M | $18.97M | $13.12M | $17.5M | $20.62M | $9.87M | $12.92M | $13.52M | |
| — | — | 34.67% | 46.43% | 77.73% | 78.24% | 72.28% | 68.1% | 55.3% | 51.4% | 60.33% | 58.18% | 53.58% | 55.65% | 58.86% | 53138.65% | 58.16% | 49.08% | |
| $10.43M | $15.59M | $12.78M | $51.2M | $70.91M | $32.69M | $16.94M | $13.74M | $10.85M | $3.08M | $99.39K | $219.82K | $5575 | $4745 | $5277 | $10.93K | $381 | $105.92K | |
| — | $19.94M | $24.61M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| $28.22M | — | $31.18M | $48.06M | $43.18M | $20.67M | $14.5M | $14.35M | $14.81M | $11.5M | $8.66M | $12.13M | $9.13M | $7.49M | $9.63M | $6.54M | $6.57M | $7.01M | |
| — | — | — | $71K | $71K | $113K | $316K | $309.23K | $275.26K | $147.01K | — | — | — | — | — | — | — | — | |
| — | $152.11K | $268.18K | $269.87K | — | — | — | — | $176.79K | $334K | $422.87K | $494.26K | $589.34K | $556.3K | $461.45K | $464.91K | $466.54K | $268.38K | |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | $1.93M | — | |
| $28.13M | $35.53M | $37.39M | $107.07M | $114.08M | $53.36M | $31.43M | $28.09M | $29.64M | $15.51M | $10.33M | $12.35M | $9.2M | $7.71M | $9.68M | $6.57M | $8.58M | $8.8M | |
| -$19.02M | -$24.75M | -$36.17M | -$93.78M | -$83.49M | $12.97M | -$14.75M | -$6.44M | -$20.87M | -$8.49M | $3.02M | $6.62M | $3.92M | $9.79M | $10.94M | $3.3M | $4.35M | $4.72M | |
| — | — | -214.19% | -575.46% | -212.14% | 21.18% | -34.62% | -20.24% | -131.57% | -62.2% | 13.64% | 20.3% | 16.02% | 31.12% | 31.23% | 17750.29% | 19.57% | 17.13% | |
| — | -$24.6M | -$35.9M | -$93.51M | — | — | — | — | -$20.7M | -$8.16M | $3.44M | $7.11M | $4.51M | $10.35M | $11.4M | $3.76M | $4.82M | $4.99M | |
| — | — | $607.47K | $2.43M | $4.37M | $4.89M | $4.62M | $4.71M | $2.95M | — | — | — | — | — | — | — | — | — | |
| $4.58M | $9.07M | $909.12K | $1.11M | -$316.06K | -$8.71M | -$5.31M | -$5.89M | -$2.2M | -$108.38K | -$204.6K | $68.63K | $33.28K | $144.26K | -$147.91K | -$63.37K | — | — | |
| -$38.23M | — | — | -$92.67M | -$83.8M | $4.27M | -$20.05M | -$12.32M | -$23.07M | -$8.6M | $2.81M | $6.69M | $3.96M | $9.93M | $10.79M | $3.23M | $4.22M | — | |
| $0 | $0 | $0 | $480.21K | $236.4K | -$3.13M | -$1.08M | -$303.93K | $866.1K | -$1.99M | $2.47M | $2.34M | $1.52M | -$4.41M | -$4.51M | -$2.17M | -$2.51M | -$1.49M | |
| -$13.95M | -$22.73M | -$37.8M | -$93.15M | -$84.04M | $7.39M | -$18.97M | -$12.02M | -$23.94M | -$6.61M | $344.73K | $4.35M | $2.43M | $14.34M | $15.3M | $5.4M | $6.74M | $6.54M | |
| — | — | -223.86% | -571.6% | -213.55% | 12.07% | -44.55% | -37.79% | -150.89% | -48.42% | 1.56% | 13.33% | 9.93% | 45.59% | 43.67% | 29081.88% | 30.32% | 23.73% | |
| — | — | — | — | — | — | — | — | -$23.94M | -$8.6M | $344.73K | $4.35M | — | — | — | $5.4M | $6.74M | $6.46M | |
| — | — | — | — | — | — | — | — | — | — | $344.73K | $4.35M | $2.43M | $14.34M | $15.3M | $5.4M | $6.74M | $6.12M | |
| USD/shares | — | -$1.55 | -$2.80 | -$11.00 | -$10.50 | $1.00 | -$2.80 | — | — | -$2.50 | $0.10 | $1.50 | $0.90 | $5.10 | $5.50 | $2.00 | $2.50 | $2.50 |
| USD/shares | — | — | — | -$11.00 | -$10.50 | $0.90 | -$2.80 | — | — | -$2.50 | $0.10 | $1.50 | $0.80 | $5.00 | $5.30 | $1.90 | $2.40 | $2.40 |
| shares | — | 14.65M | 13.49M | 8.5M | 8.01M | 7.63M | 6.68M | 6.33M | 5.39M | 3.46M | 2.87M | 2.85M | 2.85M | 2.84M | 2.77M | 2.73M | 2.7M | 2.57M |
| shares | — | — | — | 8.5M | 8.01M | 8.38M | 6.68M | 6.33M | 5.39M | 3.46M | 2.89M | 2.89M | 2.89M | 2.87M | 2.89M | 2.9M | 2.85M | 2.78M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2009–FY2015: $5.64M in buybacks, $31.51M in dividends.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Biotechnology median 8.40×
EV/EBIT
—
Biotechnology median 26.60×
P/E (TTM)
—
Biotechnology median 7.02×
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2021 | FY2020 |
|---|---|---|
| FC2 Segment | $60,396,697 | $40,556,818 |
| Preboost Segment | $862,831 | $2,035,242 |
By Geography (USD)
| Component | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| United States | $5,354,090 | $8,370,202 | $31,430,235 | $48,938,821 | $30,338,115 |
| Other Geographical Areas | $4,696,800 | $5,985,078 | — | — | — |
| Brazil | $2,760,540 | — | — | — | — |
| Mozambique | $2,172,840 | — | — | — | — |
| South Africa | $1,902,149 | $1,941,678 | — | — | — |
| Other Countries | — | — | $7,924,117 | $12,320,707 | $12,253,945 |
By Product & Service (USD)
| Component | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| FC2 Female Condom | $16,886,419 | $16,283,945 | — | — |
| Product And Service Other | $0 | $13,013 | — | — |
| FC2 Global Public Health Sector | — | — | $9,128,858 | $13,926,249 |
| FC2 Products | — | — | $39,351,937 | $60,396,697 |
| FC2 U.S. Prescription Channel | — | — | $30,223,079 | $46,470,448 |
| Other Products | — | — | $2,415 | $862,831 |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | FY2021 | FY2020 |
|---|---|---|
| Sexual Health Segment | $44,015,921,000 | $26,495,126,000 |
| Corporate | $2,346,851,000 | -$24,370,763,000 |
| Research and Development Segment | -$33,390,115,000 | -$16,871,057,000 |